Androgenetic alopecia
Conditions
Interventions
Topical Treatment Group:None
Oral Treatment Group:None
Sponsors
Beijing Tsinghua Changgung Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Male, 18 to 55 years of age, inclusive; 2. Confirmed diagnosis of AGA, classified as Grade III-vertex, IV, or V according to the Hamilton-Norwood scale; 3. Having standardized global scalp photography and trichoscopic data available at baseline; capable of completing the 12-week and 24-week follow-up visits; having complete medical records and contact details; and demonstrating compliance with follow-up and data recording requirements; 4. For the prospective cohort, signed written informed consent must be obtained at baseline.
Exclusion criteria
Exclusion criteria: 1. Severe Comorbidities or Surgeries: Any uncontrolled severe systemic disease or recently unstable condition (e.g., cardiovascular, neurological, hematological, gastrointestinal, immunological, or psychiatric disorders) that may affect medication safety or outcome evaluation; or a history of major surgery within 3 months prior to baseline, or a planned major surgery during the study period; 2. Concurrent Other Types of Alopecia: Known concurrent presence of other types of hair loss, such as telogen effluvium, alopecia areata, syphilitic alopecia, scarring alopecia, or alopecia induced by malnutrition, chemotherapy, or radiotherapy; 3. Scalp Diseases or Injuries Affecting Evaluation: Any scalp disease or lesion that may interfere with efficacy evaluation, including fungal/bacterial infections, severe seborrheic dermatitis, scalp psoriasis, contact dermatitis, severe folliculitis, scalp atrophy, or significant trauma; 4. Other Conditions Affecting Hair Growth: Systemic conditions that significantly affect hair growth or its evaluation (e.g., connective tissue diseases, active inflammatory bowel disease, moderate-to-severe anemia, or significant short-term weight loss); 5. Hair Transplantation and Cosmetic Interferences: A history of hair transplantation within the past 12 months; or the requirement to wear a wig/hairpiece long-term or use hair styling products (e.g., hairspray) during the study period, which may interfere with objective evaluation; 6. Medication Exposure and Treatments Potentially Interfering with Efficacy: Topical application of medications on the hair loss area for >= 14 consecutive days within 6 months prior to baseline that may interfere with evaluation (e.g., corticosteroids, minoxidil, or medicated shampoos/solutions containing ketoconazole or similar active ingredients); Systemic use of medications within 6 months prior to baseline that may affect outcomes (e.g., corticosteroids, immunosuppressants, chemotherapy, or cytotoxic drugs); Use of finasteride or other 5a-reductase inhibitors (including oral or topical formulations) within 6 months prior to baseline; Receipt of autologous platelet-rich plasma (PRP) therapy, microneedling, or low-level laser therapy (LLLT) within 6 months prior to baseline; 7. Allergy or Intolerance: Hypersensitivity or intolerance to finasteride, minoxidil, or any of their excipients; 8. Family Planning: Having reproductive/family planning intentions during the study period; 9. Investigator Discretion: Any other conditions that, in the opinion of the investigator, may affect medication adherence or render the subject unsuitable for participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hair count (tahc) change; | — |
Secondary
| Measure | Time frame |
|---|---|
| Norwood-Hamilton Scale;Hair count (tahc) change;Variation of hair shaft diameter (tahw);Change in the ratio of terminal hair / pili + intermediate hair;Change of hair follicle proportion of single hair; | — |
Countries
China
Contacts
Public ContactHsiaoHan Tuan
Beijing Tsinghua Changgung Hospital
Outcome results
None listed